المؤلفون: Solves, Pilar, Marco-Ayala, Javier, Sanz, Miguel Ángel, Gómez-Seguí, Inés, Balaguer-Roselló, Aitana, Facal, Ana, Villalba, Marta, Montoro, Juan, Sanz, Guillermo, de la Rubia, Javier, Sanz, Jaime

المصدر: Journal of Clinical Medicine; May2023, Vol. 12 Issue 10, p3467, 10p

مصطلحات موضوعية: HEMATOPOIETIC stem cell transplantation, CORD blood transplantation, BLOOD transfusion

مستخلص: Introduction: Transfusion plays a main role in supportive treatment for patients who receive an allogeneic hematopoietic stem cell transplantation (HSCT). In this study, we compare the transfusion requirements of patients undergoing different modalities of HSCT according to different time periods. The objective is to assess the evolution of HSCT transfusion requirements over time, from a single institution. Methods: The clinical charts and transfusion records of patients who underwent HSCT of different modalities at La Fe University Hospital during a twelve-year period were reviewed (2009–2020). For analysis, we divided the overall time into three periods: 1 from 2009 to 2012, 2 from 2013 to 2016 and 3 from 2017 to 2020. The study included 855 consecutive adult HSCT: 358 HLA-matched related donors (MRD), 134 HLA-matched unrelated donors (MUD), 223 umbilical cord blood transplantation (UCBT) and 140 haploidentical transplants (Haplo-HSCT). Results: There were no significant differences in RBC and PLT requirements or transfusion independence among the three time periods for MUD and Haplo-HSCT. However, the transfusion burden increased significantly for MRD HSCT during the 2017–2020 period. Conclusion: despite HSCT modalities having evolved and changed over time, overall transfusion requirements have not significantly decreased and continue to be a cornerstone of transplantation-supportive care. [ABSTRACT FROM AUTHOR]

: Copyright of Journal of Clinical Medicine is the property of MDPI and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

المؤلفون: Hulin, Cyrille, de la Rubia, Javier, Dimopoulos, Meletios A., Terpos, Evangelos, Katodritou, Eirini, Hungria, Vania, De Samblanx, Hadewijch, Stoppa, Anne‐Marie, Aagesen, Jesper, Sargin, Deniz, Sioni, Anastasia, Belch, Andrew, Diels, Joris, Olie, Robert A., Robinson, Don, Potamianou, Anna, van de Velde, Helgi, Delforge, Michel

المساهمون: Janssen Global Services, LLC, Millennium Pharmaceuticals, Inc.

المصدر: Health Science Reports ; volume 2, issue 1 ; ISSN 2398-8835 2398-8835

الوصف: Aims Studies have shown that bortezomib retreatment is effective in relapsed/refractory multiple myeloma (MM). The observational, prospective electronic VELCADE ® OBservational Study (eVOBS) study assessed bortezomib‐based therapies for patients with MM in everyday practice. Here, we report on those patients receiving retreatment with bortezomib. Methods Consenting adults scheduled to receive bortezomib for MM were enrolled at 162 sites across Europe, Canada, Brazil, Russia, and Turkey between 2006 and 2010. Retrospective data on prior therapies and prospective observational data after bortezomib initiation were captured electronically at baseline, after every bortezomib cycle, and every 12 weeks after discontinuation or progression. Investigator‐assessed responses and adverse events (AEs) were evaluated. Results Ninety‐six of 873 patients enrolled to eVOBS received bortezomib as first retreatment for progressive disease during the prospective observation period. Median age was 62 years, 53% were male, and median number of prior therapies at retreatment was 4. Overall, 41% of patients initiated bortezomib retreatment in combination with dexamethasone, 16% in combination with lenalidomide, and 21% received monotherapy. Rate of partial response or better (≥PR) was 75% at initial bortezomib therapy, including 44% complete response (CR)/near CR (nCR); at retreatment, ≥PR rate was 46%, including 15% CR/nCR. Median progression‐free survival was 11.4 months (95% confidence interval [CI]: 9.1‐12.7) from start of initial bortezomib treatment and 6.4 months (95% CI: 4.4‐7.2) from start of retreatment. Median overall survival from start of retreatment was 17.6 months (95% CI: 14.4‐23.5). Of the 96 patients retreated with bortezomib, 77% reported an AE. Peripheral neuropathy during bortezomib retreatment occurred in 49% of patients, including 10% grade 3/4. Conclusion These data suggest that retreatment with bortezomib is a feasible option for patients with relapsed/refractory MM.

الإتاحة: https://doi.org/10.1002/hsr2.104Test

المؤلفون: Donato, Eva Maria, Fernández-Zarzoso, Miguel, Hueso, José Antonio, de la Rubia, Javier

المصدر: OncoTargets and Therapy ; volume Volume 11, page 4583-4590 ; ISSN 1178-6930

الإتاحة: https://doi.org/10.2147/ott.s141053Test
https://www.dovepress.com/getfile.php?fileID=43520Test

المؤلفون: Jakubowiak, Andrzej, Offidani, Massimo, Pégourie, Brigitte, De La Rubia, Javier, Garderet, Laurent, Laribi, Kamel, Bosi, Alberto, MARASCA, Roberto, Laubach, Jacob, Mohrbacher, Ann, Carella, Angelo Michele, Singhal, Anil K., Tsao, L. Claire, Lynch, Mark, Bleickardt, Eric, Jou, Ying Ming, Robbins, Michael, Palumbo, Antonio

المساهمون: Jakubowiak, Andrzej, Offidani, Massimo, Pégourie, Brigitte, De La Rubia, Javier, Garderet, Laurent, Laribi, Kamel, Bosi, Alberto, Marasca, Roberto, Laubach, Jacob, Mohrbacher, Ann, Carella, Angelo Michele, Singhal, Anil K., Tsao, L. Claire, Lynch, Mark, Bleickardt, Eric, Jou, Ying Ming, Robbins, Michael, Palumbo, Antonio

مصطلحات موضوعية: Biochemistry, Immunology, Medicine (all), Hematology, Cell Biology

الوصف: In this proof-of-concept, open-label, phase 2 study, patients with relapsed/refractory multiple myeloma (RRMM) received elotuzumab with bortezomib and dexamethasone (EBd) or bortezomib and dexamethasone (Bd) until disease progression/unacceptable toxicity. Primary endpoint was progression-free survival (PFS); secondary/exploratory endpoints included overall response rate (ORR) and overall survival (OS). Two-sided 0.30 significance level was specified (80% power, 103 events) to detect hazard ratio (HR) of 0.69. Efficacy and safety analyses were performed on all randomized patients and all treated patients, respectively. Of 152 randomized patients (77 EBd, 75 Bd), 150 were treated (75 EBd, 75 Bd). PFS was greater with EBd vs Bd (HR, 0.72; 70% confidence interval [CI], 0.59-0.88; stratified log-rank P 5 .09); median PFS was longer with EBd (9.7 months) vs Bd (6.9 months). In an updated analysis, EBd-treated patients homozygous for the high-affinity FcγRIIIa allele had median PFS of 22.3 months vs 9.8 months in EBd-treated patients homozygous for the low-affinity allele. ORR was 66% (EBd) vs 63% (Bd). Very good partial response or better occurred in 36% of patients (EBd) vs 27% (Bd). Early OS results, based on 40 deaths, revealed an HR of 0.61 (70% CI, 0.43-0.85). To date, 60 deaths have occurred (28 EBd, 32 Bd). No additional clinically significant adverse events occurred with EBd vs Bd. Grade 1/2 infusion reaction rate was low (5% EBd) and mitigated with premedication. In patients with RRMM, elotuzumab, an immunostimulatory antibody, appears to provide clinical benefit without added clinically significant toxicity when combined with Bd vs Bd alone. Registered to ClinicalTrials.gov as NCT01478048.

وصف الملف: STAMPA

العلاقة: info:eu-repo/semantics/altIdentifier/pmid/27091875; info:eu-repo/semantics/altIdentifier/wos/WOS:000378335900014; volume:127(23); firstpage:2833; lastpage:2840; numberofpages:8; journal:BLOOD; http://hdl.handle.net/11380/1112426Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-84974633304; http://www.bloodjournal.org/content/127/23/2833Test

الإتاحة: https://doi.org/10.1182/blood-2016-01-694604Test
http://hdl.handle.net/11380/1112426Test
http://www.bloodjournal.org/content/127/23/2833Test

المؤلفون: Lahuerta, Juan José, Paiva, Bruno, Vidriales Vicente, María Belén, Cordón, Lourdes, Cedena, Teresa, Puig Morón, Noemí, Martinez-Lopez, Joaquin, Rosiñol, Laura, Gutiérrez Gutiérrez, Norma Carmen, Martín-Ramos, María-Luisa, Oriol, Albert, Teruel, Ana-Isabel, Echeveste, María-Asunción, de Paz, Raquel, de Arriba, Felipe, Hernandez, Miguel T., Palomera, Luis, Martinez, Rafael, Martin, Alejandro, Alegre, Adrian, De la Rubia, Javier, Orfao de Matos Correia e Vale, José Alberto, Mateos Manteca, María Victoria, Bladé, Joan, San Miguel Izquierdo, Jesús Fernando

مصطلحات موضوعية: Instituto de Investigación Biomédica de Salamanca, Multiple Myeloma, PETHEMA, GEM, Clinical oncology, Clinical Trial, Medical Oncology, oncología médica, ensayo clínico

الوصف: [EN] Purpose—To perform a critical analysis on the impact of depth of response in newly diagnosed multiple myeloma (MM). Patients and Methods—Data were analyzed from 609 patients who were enrolled in the GEM (Grupo Español de Mieloma) 2000 and GEM2005MENOS65 studies for transplant-eligible MM and the GEM2010MAS65 clinical trial for elderly patients with MM who had minimal residual disease (MRD) assessments 9 months after study enrollment. Median follow-up of the series was 71 months. Results—Achievement of complete remission (CR) in the absence of MRD negativity was not associated with prolonged progression-free survival (PFS) and overall survival (OS) compared with near-CR or partial response (median PFS, 27, 27, and 29 months, respectively; median OS, 59, 64, and 65 months, respectively). MRD-negative status was strongly associated with prolonged PFS (median, 63 months; P < .001) and OS (median not reached; P < .001) overall and in subgroups defined by prior transplantation, disease stage, and cytogenetics, with prognostic superiority of MRD negativity versus CR particularly evident in patients with high-risk cytogenetics. Accordingly, Harrell C statistics showed higher discrimination for both PFS and OS in Cox models that included MRD (as opposed to CR) for response assessment. Superior MRD-negative rates after different induction regimens anticipated prolonged PFS. Among 34 MRD-negative patients with MM and a phenotypic pattern of bone marrow involvement similar to monoclonal gammopathy of undetermined significance at diagnosis, the probability of “operational cure” was high; median PFS was 12 years, and the 10-year OS rate was 94%. Conclusion—Our results demonstrate that MRD-negative status surpasses the prognostic value of CR achievement for PFS and OS across the disease spectrum, regardless of the type of treatment or patient risk group. MRD negativity should be considered as one of the most relevant end points for transplant-eligible and elderly fit patients with MM.

العلاقة: https://dx.doi.org/10.1200%2FJCO.2016.69.2517Test; Lahuerta, J. J., Paiva, B., et al. (2017). Depth of response in multiple myeloma: a pooled analysis of three PETHEMA/GEM clinical trials. Journal of clinical oncology: official journal of the American Society of Clinical Oncology, 35(25), 2900.; http://hdl.handle.net/10366/140749Test

الإتاحة: https://doi.org/10.1200/JCO.2016.69.2517Test
http://hdl.handle.net/10366/140749Test

المؤلفون: Hájek, R., Masszi, T., Petrucci, M. T., Palumbo, A., Rosiñol, L., Nagler, Arnon., Yong, K. L., Oriol, Albert, Minarik, J., Pour, L., Dimopoulos, Meletios, Maisnar, V., Rossi, Davide, Kasparu, H., Van Droogenbroeck, J., Yehuda, D. B., Hardan, I., Jenner, M., Calbecka, M., Dávid, M., de la Rubia, Javier, Drach, J., Gasztonyi, Z., Górnik, S., Leleu, Xavier, Munder, M., Offidani, M., Zojer, N., Rajangam, K., Chang, Y. L., San-Miguel, J. F., Ludwig, H.

الوصف: This randomized, phase III, open-label, multicenter study compared carfilzomib monotherapy against low-dose corticosteroids and optional cyclophosphamide in relapsed and refractory multiple myeloma (RRMM). Relapsed and refractory multiple myeloma patients were randomized (1:1) to receive carfilzomib (10-min intravenous infusion; 20 mg/m2 on days 1 and 2 of cycle 1; 27 mg/m2 thereafter) or a control regimen of low-dose corticosteroids (84 mg of dexamethasone or equivalent corticosteroid) with optional cyclophosphamide (1400 mg) for 28-day cycles. The primary endpoint was overall survival (OS). Three-hundred and fifteen patients were randomized to carfilzomib (n = 157) or control (n = 158). Both groups had a median of five prior regimens. In the control group, 95% of patients received cyclophosphamide. Median OS was 10.2 (95% confidence interval (CI) 8.4-14.4) vs 10.0 months (95% CI 7.7-12.0) with carfilzomib vs control (hazard ratio = 0.975; 95% CI 0.760-1.249; P = 0.4172). Progression-free survival was similar between groups; overall response rate was higher with carfilzomib (19.1 vs 11.4%). The most common grade ⩾3 adverse events were anemia (25.5 vs 30.7%), thrombocytopenia (24.2 vs 22.2%) and neutropenia (7.6 vs 12.4%) with arfilzomib vs control. Median OS for single-agent carfilzomib was similar to that for an active doublet control regimen in heavily pretreated RRMM patients.

وصف الملف: application/pdf

العلاقة: Leukemia; Vol. 31 (2017), p. 107-114; https://ddd.uab.cat/record/196266Test; urn:10.1038/leu.2016.176; urn:oai:ddd.uab.cat:196266; urn:pmid:27416912; urn:scopus_id:84978544451; urn:wos_id:000394058700014; urn:altmetric_id:9049319; urn:articleid:14765551v31p107; urn:pmc-uid:5220126; urn:pmcid:PMC5220126; urn:oai:pubmedcentral.nih.gov:5220126

الإتاحة: https://ddd.uab.cat/record/196266Test

المؤلفون: Casanova, Bonaventura, Jarque, Isidro, Gascón, Francisco, Hernández-Boluda, Juan Carlos, Pérez-Miralles, Francisco, de la Rubia, Javier, Alcalá, Carmen, Sanz, Jaime, Mallada, Javier, Cervelló, Angeles, Navarré, Arantxa, Carcelén-Gadea, María, Boscá, Isabel, Gil-Perotin, Sara, Solano, Carlos, Sanz, Miguel Angel, Coret, Francisco

المصدر: Neurological Sciences ; volume 38, issue 7, page 1213-1221 ; ISSN 1590-1874 1590-3478

مصطلحات موضوعية: Psychiatry and Mental health, Neurology (clinical), Dermatology, General Medicine

الإتاحة: https://doi.org/10.1007/s10072-017-2933-6Test

المؤلفون: Román, Elena, Mendizábal, Santiago, Jarque, Isidro, de la Rubia, Javier, Sempere, Amparo, Morales, Enrique, Praga, Manuel, Ávila, Ana, Górriz, José Luis

المصدر: Nefrología ; volume 37, issue 5, page 478-491 ; ISSN 0211-6995

مصطلحات موضوعية: Nephrology

الإتاحة: https://doi.org/10.1016/j.nefro.2017.01.006Test
https://api.elsevier.com/content/article/PII:S0211699517300437?httpAccept=text/xmlTest
https://api.elsevier.com/content/article/PII:S0211699517300437?httpAccept=text/plainTest

المؤلفون: Román, Elena, Mendizábal, Santiago, Jarque, Isidro, de la Rubia, Javier, Sempere, Amparo, Morales, Enrique, Praga, Manuel, Ávila, Ana, Górriz, José Luis

المصدر: Nefrología (English Edition) ; volume 37, issue 5, page 478-491 ; ISSN 2013-2514

مصطلحات موضوعية: Nephrology

الإتاحة: https://doi.org/10.1016/j.nefroe.2017.08.001Test
https://api.elsevier.com/content/article/PII:S201325141730144X?httpAccept=text/xmlTest
https://api.elsevier.com/content/article/PII:S201325141730144X?httpAccept=text/plainTest

المؤلفون: Villalba, Ana, Gonzalez-Rodriguez, Ana Pilar, Arzuaga-Mendez, Javier, Puig, Noemí, Arnao, Mario, Arguiñano, José María, Jimenez, María, Canet, Marta, Teruel, Ana I., Sola, María, Díaz, Francisco J., Encinas, Cristina, Garcia, Antonio, Rosiñol, Laura, Suárez, Alexia, Gonzalez, Marta Sonia, Izquierdo, Isabel, Hernández, Miguel Teodoro, Infante, María Stefania, Sánchez, María José, Sampol, Antonia, de la Rubia, Javier

المصدر: Leukemia & Lymphoma ; volume 63, issue 14, page 3438-3447 ; ISSN 1042-8194 1029-2403

الإتاحة: https://doi.org/10.1080/10428194.2022.2123229Test